Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1985 Aug;28(2):265–273. doi: 10.1128/aac.28.2.265

High-pressure liquid chromatographic methods for determining arabinosyladenine-5'-monophosphate, arabinosyladenine, and arabinosylhypoxanthine in plasma and urine.

W P McCann, L M Hall, W Siler, N Barton, R J Whitley
PMCID: PMC180230  PMID: 2423028

Abstract

New high-pressure liquid chromatographic methods for determining concentrations of arabinosyladenine (Ara-A), its 5'-monophosphate (Ara-AMP), and arabinosylhypoxanthine (Ara-H) in plasma and urine are presented. A fluorescence detector is used for Ara-A and Ara-AMP, which are first converted to highly fluorescent derivatives with chloroacetaldehyde. This increases sensitivity greatly over previous methods. The sensitivities of the methods (in micrograms per milliliter) are as follows: in plasma, Ara-AMP, 0.002; Ara-A, 0.0015; and Ara-H, 0.35; and in urine, 9 times these values, respectively. Drug concentration data are also presented, which were obtained after doses of Ara-AMP were given intramuscularly to two patients treated with this drug for severe herpes zoster. One patient was given 13 mg of Ara-AMP per kg of body weight once daily, and the other was given 6.5 mg/kg twice daily. Peak Ara-AMP and Ara-A levels in plasma occurred within 1 h after the doses, and neither exceeded 2 micrograms/ml. Ara-AMP and Ara-A concentrations in plasma fell to less than 0.01 micrograms/ml in both patients by 4 to 6 h after the doses. Peak Ara-H concentrations in plasma occurred within 1 to 2 h after doses and were 21 micrograms/ml in patient 1 and 2. The highest concentration of Ara-AMP in urine was 0.09 micrograms/ml. The highest Ara-A concentration in urine was 62 micrograms/ml, and the highest Ara-H concentration in urine was 1,080 micrograms/ml. An interfering substance of unknown nature, cochromatographing with Ara-H, was encountered sporadically in urine samples. An algorithm based on differential spectrophotometry to identify and correct for this problem is described. Estimates of the renal clearances of Ara-AMP, Ara-A, and Ara-H are also given.

Full text

PDF
265

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aronoff G. R., Szwed J. J., Nelson R. L., Marcus E. L., Kleit S. A. Hypoxanthine-arabinoside pharmacokinetics after adenine arabinoside administration to a patient with renal failure. Antimicrob Agents Chemother. 1980 Jul;18(1):212–214. doi: 10.1128/aac.18.1.212. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bowman D. B., Kauffman R. E. Reversed-phase high-performance liquid chromatographic method to determine vidarabine and hypoxanthine arabinoside in biological fluids. J Chromatogr. 1982 May 14;229(2):487–491. doi: 10.1016/s0378-4347(00)84296-6. [DOI] [PubMed] [Google Scholar]
  3. Bryson Y. J., Sweetman L., Connor J. D. Simple sensitive microbioassay for adenine arabinoside and hypoxanthine arabinoside in human plasma. Antimicrob Agents Chemother. 1978 Dec;14(6):909–915. doi: 10.1128/aac.14.6.909. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Buchanan R. A., Kinkel A. W., Alford C. A., Jr, Whitley R. J. Plasma levels and urinary excretion of vidarabine after repeated dosing. Clin Pharmacol Ther. 1980 May;27(5):690–696. doi: 10.1038/clpt.1980.98. [DOI] [PubMed] [Google Scholar]
  5. Capogrossi M. C., Holdiness M. R., Israili Z. H. Determination of adenosine in normal human plasma and serum by high-performance liquid chromatography. J Chromatogr. 1982 Jan 8;227(1):168–173. doi: 10.1016/s0378-4347(00)80367-9. [DOI] [PubMed] [Google Scholar]
  6. Cockshott W. P., Thompson G. T., Howlett L. J., Seeley E. T. Intramuscular or intralipomatous injections? N Engl J Med. 1982 Aug 5;307(6):356–358. doi: 10.1056/NEJM198208053070607. [DOI] [PubMed] [Google Scholar]
  7. Friedman H. M. Adenine arabinoside and allopurinol--possible adverse drug interaction. N Engl J Med. 1981 Feb 12;304(7):423–423. [PubMed] [Google Scholar]
  8. HARE R. S. Endogenous creatinine in serum and urine. Proc Soc Exp Biol Med. 1950 May;74(1):148–151. doi: 10.3181/00379727-74-17837. [DOI] [PubMed] [Google Scholar]
  9. Preiksaitis J. K., Lank B., Ng P. K., Brox L., LePage G. A., Tyrrell D. L. Effect of liver disease on pharmacokinetics and toxicity of 9-beta-D-arabinofuranosyladenine-5-phosphate. J Infect Dis. 1981 Oct;144(4):358–364. doi: 10.1093/infdis/144.4.358. [DOI] [PubMed] [Google Scholar]
  10. Roos H., Pfleger K. Kinetics of adenosine uptake by erythrocytes, and the influence of dipyridamole. Mol Pharmacol. 1972 Jul;8(4):417–425. [PubMed] [Google Scholar]
  11. Schneider H. G., Glazko A. J. High-performance liquid chromatography of adenine and hypoxanthine arabinosides. J Chromatogr. 1977 Sep 21;139(2):370–375. doi: 10.1016/s0021-9673(00)89334-6. [DOI] [PubMed] [Google Scholar]
  12. Shope T. C., Kauffman R. E., Bowman D., Marcus E. L. Pharmacokinetics of vidarabine in the treatment of infants and children with infections due to herpesviruses. J Infect Dis. 1983 Oct;148(4):721–725. doi: 10.1093/infdis/148.4.721. [DOI] [PubMed] [Google Scholar]
  13. Whitley R. J., Soong S. J., Dolin R., Betts R., Linnemann C., Jr, Alford C. A., Jr Early vidarabine therapy to control the complications of herpes zoster in immunosuppressed patients. N Engl J Med. 1982 Oct 14;307(16):971–975. doi: 10.1056/NEJM198210143071602. [DOI] [PubMed] [Google Scholar]
  14. Whitley R. J., Tucker B. C., Kinkel A. W., Barton N. H., Pass R. F., Whelchel J. D., Cobbs C. G., Diethelm A. G., Buchanan R. A. Pharmacology, tolerance, and antiviral activity of vidarabine monophosphate in humans. Antimicrob Agents Chemother. 1980 Nov;18(5):709–715. doi: 10.1128/aac.18.5.709. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Whitley R., Hilty M., Haynes R., Bryson Y., Connor J. D., Soong S. J., Alford C. A. Vidarabine therapy of varicella in immunosuppressed patients. J Pediatr. 1982 Jul;101(1):125–131. doi: 10.1016/s0022-3476(82)80201-1. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES